USFDAJun 18, 2026, 09:02 AM
Cadrenal to Seek FDA Rare Pediatric Designation for Tecarfarin; Potential $200M PRV
AI Summary
Cadrenal Therapeutics announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the FDA for tecarfarin as a treatment for pediatric patients with Kawasaki disease who develop coronary artery aneurysms. If the designation is granted and tecarfarin is approved, Cadrenal would be eligible to receive a Priority Review Voucher, which has recent open-market valuations of approximately $200 million. The company will highlight this initiative and its Phase 3-ready CAD-1005 platform at the upcoming BIO International Convention.
Key Highlights
- Cadrenal to submit Rare Pediatric Disease Designation (RPDD) request to FDA for tecarfarin in Kawasaki disease.
- If granted, company eligible for a Priority Review Voucher (PRV).
- Recent open-market valuations for PRVs reached ~$200 million, ranging from $180 million to $205 million.
- Tecarfarin is a novel Vitamin K antagonist designed to offer more stable anticoagulation than warfarin.
- Company to present its pipeline, including tecarfarin and CAD-1005, at the 2026 BIO International Convention.
- CAD-1005 is Phase 3-ready for Heparin-Induced Thrombocytopenia (HIT) and in Phase 2a for CSA-AKI.
- Kawasaki disease incidence is 10 to 15 times higher in Japanese and East Asian populations.
Price Impact
More from CVKD